Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Navamedic ASA: Prolongation of Mysimba® distribution agreement

NAVAPress release20.10.2026 klo 09.45

Oslo, 20 October 2026 - Navamedic ASA has secured a five-year prolongation of the Nordic rights to Mysimba® - an oral tablet prescribed for the treatment of obesity. 

"We are pleased to announce a prolongation of the Nordic rights to distribute and market Mysimba®. We are also pleased to collaborate with Azurity who as the new global owner of Mysimba will increase the support to local partners like Navamedic," says Lars Minor, Chief Executive Officer of Navamedic.
 
Navamedic has distributed Mysimba® (naltrexone/bupropion) in the Nordic region since 2017 under a long-term exclusive agreement with the product's previous owners. In 2026, the product and associated rights were acquired by Azurity Pharmaceuticals.
 
"Mysimba® remains an important product to Navamedic, and we appreciate the new partnership with Azurity and jointly aim to ensure continued availability of Mysimba® in the Nordic markets. With the renewal of this agreement and new partnership with Azurity, we look forward to exploring further collaboration opportunities for additional products in the future," Lars Minor concludes.
 
Navamedic and Azurity have agreed to extend the existing distribution agreement on largely similar terms for additional five years with an upfront licensing fee. The effective date of the agreement is 26 April 2027, and the revised terms of the agreement are implemented from this date. 
 
For further information, please contact:

Lars Minor, CEO, mobile: +45 20 89 62 00
Nils Ole Krekling, CFO, mobile: +47 924 24 016

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.